missing translation for 'onlineSavingsMsg'
Learn More
Learn More
R&D Systems™ Recombinant Human VSIG4 Short Isoform Fc Chimera Protein
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility.
Marke: R&D Systems™ 9817-VS-050
285.09 EUR gültig bis 2024-12-16
Benutzen Sie den Promotions-Code "21630" um Ihren Promotions-Preis zu erhalten.
Dieser Artikel kann nicht zurückgegeben werden.
Rückgaberichtlinie anzeigen
Beschreibung
Measured by its ability to inhibit anti-CD3 antibody induced IFN-gamma secretion by human peripheral blood mononuclear cells (PBMC). The ED50 for this effect is 1-5 μg/mL.Spezifikation
| Q9Y279-3 | |
| Lyophilized from a 0.2 μm filtered solution in PBS. | |
| M.W. (Observed): 55-65 kDa, reducing conditions; M.W. (theoretical): 46 kDa | |
| 50 μg | |
| Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20°C to -70°C as supplied. 1 month, 2°C to 8°C under sterile conditions after reconstitution. 3 months, -20°C to -70°C under sterile conditions after reconstitution. | |
| Unconjugated | |
| Reconstitute at 200 μg/mL in PBS. | |
| VSIG4 |
| Bioactivity | |
| 11326 | |
| CRIg, Ig superfamily protein, Protein Z39Ig, V-set and immunoglobulin domain containing 4, V-set and immunoglobulin domain-containing protein 4, Z39IG, Z39IGcomplement receptor of the immunoglobulin superfamily | |
| Chinese Hamster Ovary cell line, CHO-derived human VSIG4 protein Human VSIG4 (Arg20-Pro189) (N-terminus) Accession # Q9Y279-3 IEGRMD Human IgG1 (Pro100-Lys330) (C-terminus) | |
| <0.10 EU / 1 μg of the protein by the LAL method. | |
| Human | |
| >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie™ Blue Staining. |